Nature Medicine, Published online: 07 January 2026; doi:10.1038/s41591-025-04101-y
In a multicenter, randomized trial of patients with atrial fibrillation and a low risk of thromboembolic events, treatment with the anticoagulant rivaroxaban showed no benefit in reducing cognitive decline, stroke or transient ischemic attack when compared to placebo.
At Srivax, we believe in delivering fast, accurate, and relevant news to empower, inform, and engage our readers across the globe. We are an independent digital news platform built for the modern world — where information moves fast, and truth matters.
online health in partnership with a renowned telehealth ; glp-1, weight loss etc https://srivax.telehealthwebsite.com/
